公开(公告)号：US20160355457A1

公开(公告)日：2016-12-08

申请号：US15164394

申请日：2016-05-25

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Michael Sizensky ,  Harold S. Wilkinson ,  John R. Snoonian ,  Norman Kim ,  Sharon M. Laughlin ,  Roger P. Bakale ,  Kevin Plunkett ,  Patrick Mousaw

IPC: C07C215/64

CPC classification number: C07C215/64 ,  C07B2200/07 ,  C07B2200/13 ,  C07C213/10 ,  C07C2601/14

Abstract: Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Abstract translation: 本文提供了包含可用于治疗，预防和治疗各种病症和疾病的化合物的固体形式。 特别地，本发明提供了包含（ - ） - O-去甲基文拉法辛（包括其盐）的固体形式，其可用于治疗，预防和治疗病症和病症，包括但不限于情感障碍如抑郁症，双相和躁狂症 失调，注意力缺陷障碍，具有多动症的注意力缺陷障碍，帕金森病，癫痫，脑功能障碍，肥胖和体重增加，失禁，痴呆和相关疾病。

公开(公告)号：US20180071230A1

公开(公告)日：2018-03-15

申请号：US15631909

申请日：2017-06-23

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Sharon M. Laughlin ,  Michael J. Sizensky ,  Surendra P. Singh ,  Harold Scott Wilkinson ,  Cai Gu Huang ,  Philip James Bonasia ,  Susan S. D'Souza

IPC: A61K31/135 ,  C07C211/42 ,  A61K9/20 ,  A61K9/48

CPC classification number: A61K31/135 ,  A61K9/2018 ,  A61K9/4858 ,  C07C211/42

Abstract: Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.